{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:19Z","timestamp":1793146639647,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Key Research and Development Plan","award":["2022YFC3601900"],"award-info":[{"award-number":["2022YFC3601900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05301-0","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:02:10Z","timestamp":1775887330000},"page":"14191-14202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association study of aromatase inhibitors and adverse events related to osteoporosis: based on pharmacovigilance data"],"prefix":"10.1007","volume":"399","author":[{"given":"Nan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leimin","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"5301_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2217\/pgs-2023-0199","volume":"25","author":"S Abudahab","year":"2024","unstructured":"Abudahab S, Slattum PW, Price ET, McClay JL (2024) Epigenetic regulation of drug metabolism in aging: utilizing epigenetics to optimize geriatric pharmacotherapy. Pharmacogenomics 25:41\u201354. https:\/\/doi.org\/10.2217\/pgs-2023-0199","journal-title":"Pharmacogenomics"},{"key":"5301_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.amjmed.2022.02.035","volume":"135","author":"D Alsoof","year":"2022","unstructured":"Alsoof D, Anderson G, McDonald CL, Basques B, Kuris E, Daniels AH (2022) Diagnosis and management of vertebral compression fracture. Am J Med 135:815\u2013821. https:\/\/doi.org\/10.1016\/j.amjmed.2022.02.035","journal-title":"Am J Med"},{"key":"5301_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1200\/JOP.0768501","volume":"3","author":"T Bao","year":"2007","unstructured":"Bao T, Davidson NE (2007) How we maintain bone health in early-stage breast cancer patients on aromatase inhibitors. J Oncol Pract 3:323\u2013325. https:\/\/doi.org\/10.1200\/JOP.0768501","journal-title":"J Oncol Pract"},{"key":"5301_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/BCTT.S29432","volume":"4","author":"M Bauer","year":"2012","unstructured":"Bauer M, Bryce J, Hadji P (2012) Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Medical Press) 4:91\u2013101. https:\/\/doi.org\/10.2147\/BCTT.S29432","journal-title":"Breast Cancer (Dove Medical Press)"},{"key":"5301_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031376","author":"C Cheng","year":"2022","unstructured":"Cheng C, Chen L, Chen K (2022) Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23031376","journal-title":"Int J Mol Sci"},{"key":"5301_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.metabol.2019.06.010","volume":"98","author":"S Christakos","year":"2019","unstructured":"Christakos S, Li S, De La Cruz J, Bikle DD (2019) <article-title update=\"added\">New developments in our understanding of vitamin D metabolism, action and treatment. Metabolism 98:112\u2013120. https:\/\/doi.org\/10.1016\/j.metabol.2019.06.010","journal-title":"Metabolism"},{"key":"5301_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092. https:\/\/doi.org\/10.1056\/NEJMoa040331","journal-title":"N Engl J Med"},{"key":"5301_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103679","author":"A Corrado","year":"2020","unstructured":"Corrado A, Cici D, Rotondo C, Maruotti N, Cantatore FP (2020) Molecular basis of bone aging. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21103679","journal-title":"Int J Mol Sci"},{"key":"5301_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/FPC.0b013e32832e0ec1","volume":"19","author":"Z Desta","year":"2009","unstructured":"Desta Z, Nguyen A, Flockhart D, Skaar T, Fletcher R, Weinshilboum R et al (2009) Antiestrogen pathway (aromatase inhibitor). Pharmacogenet Genomics 19:554\u2013555. https:\/\/doi.org\/10.1097\/FPC.0b013e32832e0ec1","journal-title":"Pharmacogenet Genomics"},{"key":"5301_CR10","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/jbmr.4644","volume":"37","author":"ML Doolittle","year":"2022","unstructured":"Doolittle ML, Saul D, Kaur J, Rowsey JL, Eckhardt B, Vos S et al (2022) Skeletal effects of inducible ER\u03b1 deletion in osteocytes in adult mice. J Bone Miner Res 37:1750\u20131760. https:\/\/doi.org\/10.1002\/jbmr.4644","journal-title":"J Bone Miner Res"},{"key":"5301_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-023-06605-5","volume":"24","author":"H Ferris","year":"2023","unstructured":"Ferris H, Merron G, Coughlan T (2023) 1 year mortality after hip fracture in an Irish urban trauma centre. BMC Musculoskelet Disord 24:487. https:\/\/doi.org\/10.1186\/s12891-023-06605-5","journal-title":"BMC Musculoskelet Disord"},{"key":"5301_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jbspin.2003.02.001","volume":"71","author":"E Fontanges","year":"2004","unstructured":"Fontanges E, Fontana A, Delmas P (2004) Osteoporosis and breast cancer. Joint Bone Spine 71:102\u2013110. https:\/\/doi.org\/10.1016\/j.jbspin.2003.02.001","journal-title":"Joint Bone Spine"},{"key":"5301_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2818","volume":"13","author":"S Gaillard","year":"2011","unstructured":"Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13:205. https:\/\/doi.org\/10.1186\/bcr2818","journal-title":"Breast Cancer Res"},{"key":"5301_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biom13030483","author":"Y Gao","year":"2023","unstructured":"Gao Y, Chen N, Fu Z, Zhang Q (2023) Progress of Wnt signaling pathway in osteoporosis. Biomolecules. https:\/\/doi.org\/10.3390\/biom13030483","journal-title":"Biomolecules"},{"key":"5301_CR15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/bjc.2011.58","volume":"104","author":"J Geisler","year":"2011","unstructured":"Geisler J (2011) Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole\u2013of clinical importance. Br J Cancer 104:1059\u20131066. https:\/\/doi.org\/10.1038\/bjc.2011.58","journal-title":"Br J Cancer"},{"key":"5301_CR16","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.1097\/00007632-199712151-00003","volume":"22","author":"DL Glaser","year":"1997","unstructured":"Glaser DL, Kaplan FS (1997) Osteoporosis. Definition and clinical presentation. Spine (Phila Pa 1976) 22:12S-16S. https:\/\/doi.org\/10.1097\/00007632-199712151-00003","journal-title":"Spine (Phila Pa 1976)"},{"key":"5301_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091487","author":"W Glinkowski","year":"2019","unstructured":"Glinkowski W, Narloch J, Krasuski K, \u015aliwczy\u0144ski A (2019) The increase of osteoporotic hip fractures and associated one-year mortality in Poland: 2008-2015. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8091487","journal-title":"J Clin Med"},{"key":"5301_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","volume":"20","author":"A Goldhirsch","year":"2009","unstructured":"Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Th\u00fcrlimann B, Senn H et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319\u20131329. https:\/\/doi.org\/10.1093\/annonc\/mdp322","journal-title":"Ann Oncol"},{"key":"5301_CR19","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262\u20131271. https:\/\/doi.org\/10.1093\/jnci\/dji250","journal-title":"J Natl Cancer Inst"},{"key":"5301_CR20","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1200\/JCO.2012.44.7805","volume":"31","author":"PE Goss","year":"2013","unstructured":"Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - a randomized controlled phase III trial. J Clin Oncol 31:1398\u20131404. https:\/\/doi.org\/10.1200\/JCO.2012.44.7805","journal-title":"J Clin Oncol"},{"key":"5301_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209\u2013219. https:\/\/doi.org\/10.1056\/NEJMoa1604700","journal-title":"N Engl J Med"},{"key":"5301_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/tpj.2016.60","volume":"17","author":"DL Hertz","year":"2017","unstructured":"Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA et al (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521\u2013527. https:\/\/doi.org\/10.1038\/tpj.2016.60","journal-title":"Pharmacogenomics J"},{"key":"5301_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 365:60\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(04)17666-6","journal-title":"Lancet"},{"key":"5301_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju055","journal-title":"J Natl Cancer Inst"},{"key":"5301_CR25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert LA, Gumusay O, Idossa D, Rugo HS (2023) Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin 73:480\u2013515. https:\/\/doi.org\/10.3322\/caac.21777","journal-title":"CA Cancer J Clin"},{"key":"5301_CR26","first-page":"21","volume":"58","author":"G Iancu","year":"2017","unstructured":"Iancu G, Vasile D, Iancu RC, Davi\u0162oiu DV (2017) Triple positive\u201d breast cancer - a novel category. Rom J Morphol Embryol 58:21\u201326","journal-title":"Rom J Morphol Embryol"},{"key":"5301_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368\u2013381. https:\/\/doi.org\/10.1007\/BF01622200","journal-title":"Osteoporos Int"},{"key":"5301_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82. https:\/\/doi.org\/10.1007\/s11657-020-00871-9","journal-title":"Arch Osteoporos"},{"key":"5301_CR29","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E et al (2025) Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 31:1154\u20131162. https:\/\/doi.org\/10.1038\/s41591-025-03502-3","journal-title":"Nat Med"},{"key":"5301_CR30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.4143\/crt.2023.846","volume":"55","author":"EY Lee","year":"2023","unstructured":"Lee EY, Lee D, Lee K, Im S (2023) Recent developments in the therapeutic landscape of advanced or metastatic hormone receptor-positive breast cancer. Cancer Res Treat 55:1065\u20131076. https:\/\/doi.org\/10.4143\/crt.2023.846","journal-title":"Cancer Res Treat"},{"key":"5301_CR31","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1634\/theoncologist.2019-0149","volume":"24","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Morin SN, Lix LM, Niraula S, McCloskey EV, Johansson H et al (2019) Fracture risk in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study. Oncologist 24:1432\u20131438. https:\/\/doi.org\/10.1634\/theoncologist.2019-0149","journal-title":"Oncologist"},{"key":"5301_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241303428","volume":"15","author":"R Liu","year":"2024","unstructured":"Liu R, Chen Y, Wu S, Ma W, Qiu Z, Wang J et al (2024) Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database. Ther Adv Drug Saf 15:20420986241303428. https:\/\/doi.org\/10.1177\/20420986241303428","journal-title":"Ther Adv Drug Saf"},{"key":"5301_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/annonc\/mdq337","volume":"22","author":"PE L\u00f8nning","year":"2011","unstructured":"L\u00f8nning PE (2011) The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol 22:503\u2013514. https:\/\/doi.org\/10.1093\/annonc\/mdq337","journal-title":"Ann Oncol"},{"key":"5301_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/17455057221149493","volume":"19","author":"M Malagrin\u00f2","year":"2023","unstructured":"Malagrin\u00f2 M, Zavatta G (2023) Review of bone health in women with estrogen receptor-positive breast cancer receiving endocrine therapy. Womens Health 19:17455057221149493. https:\/\/doi.org\/10.1177\/17455057221149493","journal-title":"Womens Health"},{"key":"5301_CR35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1634\/theoncologist.2008-0055","volume":"13","author":"WR Miller","year":"2008","unstructured":"Miller WR, Bartlett J, Brodie AMH, Brueggemeier RW, Salle E, L\u00f8nning PE et al (2008) Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter. Oncologist 13:829\u2013837. https:\/\/doi.org\/10.1634\/theoncologist.2008-0055","journal-title":"Oncologist"},{"key":"5301_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.bone.2013.04.021","volume":"55","author":"N Napoli","year":"2013","unstructured":"Napoli N, Rastelli A, Ma C, Yarramaneni J, Vattikutti S, Moskowitz G et al (2013) Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer. Bone 55:309\u2013314. https:\/\/doi.org\/10.1016\/j.bone.2013.04.021","journal-title":"Bone"},{"key":"5301_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60122109","author":"S \u00d6zmen","year":"2024","unstructured":"\u00d6zmen S, Kurt S, Timur HT, Yavuz O, Kula H, Demir AY et al (2024) Prevalence and risk factors of osteoporosis: a cross-sectional study in a tertiary center. Medicina (Kaunas, Lithuania). https:\/\/doi.org\/10.3390\/medicina60122109","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"5301_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/jcm2040283","volume":"2","author":"AHG Paterson","year":"2013","unstructured":"Paterson AHG, Shea-Budgell MA (2013) Bone health in patients with breast cancer: recommendations from an evidence-based Canadian guideline. J Clin Med 2:283\u2013301. https:\/\/doi.org\/10.3390\/jcm2040283","journal-title":"J Clin Med"},{"key":"5301_CR39","unstructured":"Perez EA, Weilbaecher K (2006) Aromatase inhibitors and bone loss. Oncology (Williston Park, N.Y.) 20, 1029\u20131039; discussion 1039\u20131040, 1042, 1048"},{"key":"5301_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10549-019-05464-w","volume":"179","author":"X Qian","year":"2020","unstructured":"Qian X, Li Z, Ruan G, Tu C, Ding W (2020) Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Res Treat 179:275\u2013285. https:\/\/doi.org\/10.1007\/s10549-019-05464-w","journal-title":"Breast Cancer Res Treat"},{"key":"5301_CR41","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","volume":"20","author":"M Rabaglio","year":"2009","unstructured":"Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Th\u00fcrlimann B et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 20:1489\u20131498. https:\/\/doi.org\/10.1093\/annonc\/mdp033","journal-title":"Ann Oncol"},{"key":"5301_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5301_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01394-y","volume":"23","author":"M Rozenblit","year":"2021","unstructured":"Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S (2021) Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Res 23:14. https:\/\/doi.org\/10.1186\/s13058-021-01394-y","journal-title":"Breast Cancer Res"},{"key":"5301_CR44","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","volume":"34","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN et al (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 34:3069\u20133103. https:\/\/doi.org\/10.1200\/JCO.2016.67.1487","journal-title":"J Clin Oncol"},{"key":"5301_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S et al (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:609. https:\/\/doi.org\/10.1186\/s13018-021-02772-0","journal-title":"J Orthop Surg Res"},{"key":"5301_CR46","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2217\/fon-2017-0228","volume":"13","author":"MA \u015eendur","year":"2017","unstructured":"\u015eendur MA, Bilgin B, H\u0131zal M, \u00d6zdemir NY, Ak\u0131nc\u0131 MB, Dede D\u015e et al (2017) Do all aromatase inhibitors have similar efficacy and safety. Future Oncol 13:1673\u20131676. https:\/\/doi.org\/10.2217\/fon-2017-0228","journal-title":"Future Oncol"},{"key":"5301_CR47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, L\u00fcthy R et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309\u2013319. https:\/\/doi.org\/10.1016\/s0092-8674(00)80209-3","journal-title":"Cell"},{"key":"5301_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06614-0","volume":"7","author":"C Streicher","year":"2017","unstructured":"Streicher C, Heyny A, Andrukhova O, Haigl B, Slavic S, Sch\u00fcler C et al (2017) Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells. Sci Rep 7:6460. https:\/\/doi.org\/10.1038\/s41598-017-06614-0","journal-title":"Sci Rep"},{"key":"5301_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2584","volume":"12","author":"C Van Poznak","year":"2010","unstructured":"Van Poznak C (2010) Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition. Breast Cancer Res 12:110. https:\/\/doi.org\/10.1186\/bcr2584","journal-title":"Breast Cancer Res"},{"key":"5301_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1218206","volume":"13","author":"J Xu","year":"2023","unstructured":"Xu J, Cao B, Li C, Li G (2023) The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy. Front Oncol 13:1218206. https:\/\/doi.org\/10.3389\/fonc.2023.1218206","journal-title":"Front Oncol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05301-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:43:23Z","timestamp":1783907003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05301-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5301"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05301-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study based on publicly available datasets. The Institutional Review Board has confirmed that no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}